Bristol Myers Squibb’s BMY performance in 2025 reflects an ongoing transition in its revenue base, with growth from newer products partially offsetting continued declines in legacy drugs. Sales from ...
AbbVie ABBV has built a substantial neuroscience franchise. While the segment was initially anchored by Botox Therapeutic and the depression drug Vraylar, its offerings now include the oral migraine ...
AbbVie ABBV has built a robust neuroscience franchise over the years. Though the segment was initially heralded by blockbuster medications like Botox Therapeutic and the depression drug Vraylar, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results